Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514).
In: European journal of cancer (Oxford, England : 1990), Jg. 189 (2023-08-01), S. 112909
report
Zugriff:
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sylvain Choquet: Scientific advisory board for: Gilead; Novartis; Roche; Abbvie; Sandoz; Sanofi; Janssen; Celgene-BMS; Takeda; Atara; Astra Zeneca; Pierre Fabre; Viatris. Carole Soussain: Scientific advisory board for Gossamer. Caroline Houillier, Hervé Ghesquières and Denis Malaise: no conflict of interest.
Titel: |
Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514).
|
---|---|
Autor/in / Beteiligte Person: | Soussain, C ; Malaise, D ; Choquet, S ; Ghesquières, H ; Houillier, C |
Zeitschrift: | European journal of cancer (Oxford, England : 1990), Jg. 189 (2023-08-01), S. 112909 |
Veröffentlichung: | Oxford : Elsevier Science Ltd ; <i>Original Publication</i>: Oxford ; New York : Pergamon Press, c1990-, 2023 |
Medientyp: | report |
ISSN: | 1879-0852 (electronic) |
DOI: | 10.1016/j.ejca.2023.04.025 |
Schlagwort: |
|
Sonstiges: |
|